| Jun 18, 2025 | PreciseDx | $11.0M Other Equity | Eventide Asset Management, Merck, Philips Ventures | GenHenn Capital, Labcorp, Quest Diagnostics |
| Aug 21, 2024 | PreciseDx | $20.7M Series B | Eventide Asset Management | GenHenn Capital, Labcorp, Quest Diagnostics |
| Feb 15, 2024 | Freenome | $254.0M Other Equity | Matt Sause | American Cancer Society, Andreessen Horowitz, ARK Invest, ArrowMark Partners, Bain Capital Life Sciences, Data Collective, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Mark A. Gardner, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates |
| Sep 1, 2023 | Avalyn Pharma | $180.0M Series C | SR One, Eventide Asset Management, Gianna Hoffman-Luca | B Capital Group, Northpond Ventures, Heather Preston, Catalio Capital Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings, Pivotal bioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, Surveyor Capital, T. Rowe Price Associates, Vida Ventures, Wellington Management |
| Mar 1, 2023 | Flare Therapeutics | $120.0M Series B | Craig Gordon | 8VC, Nextech Invest, The Column Group, Third Rock Ventures, Two Sigma Ventures, Agent Capital, Boxer Capital, Casdin Capital, Eli Lilly and Company, Invus Financial Advisors, Memorial Sloan Kettering Cancer Center, Nextech Invest, Novartis, Pavilion Capital, Aaron Davis, ShangBay Capital |
| Nov 1, 2022 | Casma Therapeutics | $46.0M Series C | — | Astellas Venture Management, The Column Group, Third Rock Ventures, Amgen Ventures, Hiromichi Kimura, Eisai, Euclidean Capital, Mirae Asset, Tomotaka Okino, Schroders Capital |
| Jan 1, 2022 | Metagenomi | $180.0M Series B | Farallon Capital Management, Santhosh Palani, PhD, CFA | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Humboldt Fund, Nextech Invest, OrbiMed, RA Capital, Tencent Holdings, Jeremy Yap, Bristol Myers Squibb, Deep Track Capital, Frazier Life Sciences, Irving Investors, Leaps by Bayer, Marshall Wace, Millennium Management, Moderna, Novo Holdings, Pura Vida Investments, RA Capital Management, Surveyor Capital |
| Jan 1, 2022 | Korro Bio | $120.0M Series B | Joy Ghosh | Atlas Venture, John Hamer, Alexandria Venture Investments, Cormorant Asset Management, Fidelity Management & Research Company, Invus, Monashee Investment Management, MP Healthcare Venture Management, NEA, Alex Silverstein, Qiming Venture Partners USA, Sixty Degree Capital, Surveyor Capital, Verition Fund Management, Wu Capital |
| Dec 1, 2021 | Freenome | $300.0M Series D | Ellen Hukkelhoven, Peter Kolchinsky | Anzu Partners, Ameena El-Bibany, Vasudev Bailey, Artis Ventures (AV), Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, RA Capital, Section 32, Anne Wojcicki, Timothy A. Springer, Andreessen Horowitz, ArrowMark Partners, BrightEdge Ventures, Byers Capital, Catalio Capital Management, Data Collective, Farallon Capital Management, Fidelity Management & Research Company, Google Ventures, HBM Healthcare Investments, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente, Logos Capital, Novartis, Polaris Partners, Pura Vida Investments, Ridgeback Capital Investments, Thomas Schinecker, Rock Springs Capital, Sands Capital, Soleus Capital, Suvretta Capital Management, T. Rowe Price Associates |
| Sep 1, 2021 | LEXEO Therapeutics | $100.0M Series B | Daniel Saul Sundheim, Joy Ghosh | Omega Funds, Alexandria Venture Investments, CAM Capital, Gray's Creek Capital Partners, Invus, Janus Henderson Investors, Laurion Capital Management, Longitude Capital, Lundbeckfond Ventures, PBM Capital, Verition Fund Management, Woodline Partners |
| Aug 1, 2021 | Dice Therapeutics | $60.0M Series C | RA Capital Management, Sands Capital | RA Capital, Samsara BioCapital, Versant Ventures, Asymmetry Capital Management, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, Soleus Capital |
| Jul 1, 2021 | Turnstone Biologics | $80.0M Series D | Santhosh Palani, PhD, CFA, Point72 | KohFounders, Sofinnova Investments, venBio, Venrock, Versant Ventures, 404 Bio, Brace Pharma Capital, CaaS Capital Management, F-Prime Capital, JM Family Enterprises, Northleaf Capital Partners, OrbiMed, Ridgeback Capital Investments, Sectoral Asset Management, Sixty Degree Capital, Surveyor Capital, Takeda Ventures, Teralys Capital |
| Jun 1, 2021 | Kojin Therapeutics | $60.0M Series A | Luba Greenwood, Thomas Cahill, Amir Nashat | Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, Timothy A. Springer, Tom Hudson, Alexandria Venture Investments, Binney Street Capital, Juergen Eckhardt |
| May 23, 2021 | Arch Oncology | $105.0M Series C | Joe Biller, CFA, Eric Pham, Joy Ghosh | Adage Capital Management, Avego Healthcare Capital, Broadfin Holdings, FMB Research, Lightchain, Point72, John McKearn, Roche |
| May 1, 2021 | Flare Therapeutics | $82.0M Series A | Third Rock Ventures | Boxer Capital, Casdin Capital, Invus Financial Advisors, Nextech Invest |
| Apr 15, 2021 | Biosplice Therapeutics | $120.0M Other Equity | — | Joy Ghosh, Sands Capital, SymBiosis II, Verition Fund Management |
| Jan 1, 2021 | Dice Therapeutics | $80.0M Series C | Jake Simson | RA Capital, Samsara BioCapital, Versant Ventures, Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, Driehaus Capital Management, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, Sands Capital, Sanofi Ventures, Soleus Capital |
| Dec 17, 2020 | Cullinan Therapeutics | $131.2M Series C | Foresite Capital | Baupost Group, Boxer Capital, BVF Partners, Cowen Healthcare Investments, F2 Ventures, Leerink Partners, Logos Capital, MPM Capital, Nextech Invest, OrbiMed, Rock Springs Capital, Schooner Capital, Venrock |
| Oct 6, 2020 | Talaris Therapeutics | $115.0M Series B | Surveyor Capital, Viking Global Investors | Aisling Capital, BlackRock, Blackstone, Cormorant Asset Management, Invus, Logos Capital, Longitude Capital, Pamoja Capital, Qiming Venture Partners USA |
| Sep 1, 2020 | Casma Therapeutics | $50.0M Series B | The Column Group | Astellas Venture Management, Third Rock Ventures, Finny Kuruvilla, Schroder Adveq |
| Jul 28, 2020 | Praxis Precision Medicines | $110.0M Series C | Finny Kuruvilla | Adage Capital Management, Avoro Capital Advisors, Blackstone, Cormorant Asset Management, Irving Investors, Novo Holdings, OCV Partners, Point72, Qatar Investment Authority, Surveyor Capital, Verition Fund Management, Vida Ventures |
| Jul 5, 2020 | Freeline | $120.0M Series C Extension | Eventide Asset Management, Thomas Dyrberg, Wellington Management | Acorn Bioventures, Ample Plus Fund, Cowen Healthcare Investments |
| Jul 2, 2020 | Annexon Biosciences | $100.0M Other Equity | Redmile Group | Adage Capital Management, Bain Capital Life Sciences, BlackRock, Blackstone, Deerfield Management, Farallon Capital Management, Janus Henderson Investors, Logos Capital, New Enterprise Associates, Satter Medical Technology Partners, Surveyor Capital |
| Jun 30, 2020 | Goldfinch Biopharma | $100.0M Series B | Joy Ghosh | Ally Bridge Group, BlackRock, Casdin Capital, Gilead Sciences, Irving Investors, Schroders Capital, Wellington Management, Yonjin Capital |
| May 4, 2020 | Praxis Precision Medicines | $100.0M Other Equity | Kiran Reddy | Novo Holdings, Vida Ventures |
